Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers. Significant
efforts have largely defined major genetic factors driving PDAC pathogenesis and …

Hepatocellular carcinoma (HCC) is one of the leading cancers worldwide. Classically, HCC
develops in genetically susceptible individuals who are exposed to risk factors, especially in …

The tumor microenvironment (TME) is composed of many different cellular and acellular
components that together drive tumor growth, invasion, metastasis, and response to …

Patients with localized pancreatic ductal adenocarcinoma (PDAC) are best treated with
surgical resection of the primary tumour and systemic chemotherapy, which provides …

Single-cell atlases promise to provide a 'missing link'between genes, diseases and
therapies. By identifying the specific cell types, states, programs and contexts where disease …

Immunotherapies have shown benefits across a range of human cancers, but not pancreatic
ductal adenocarcinoma (PDAC). Recent evidence suggests that the immunosuppressive …

KRAS inhibitors demonstrate clinical efficacy in pancreatic ductal adenocarcinoma (PDAC);
however, resistance is common. Among patients with KRAS G12C-mutant PDAC treated …

The molecular dynamics of pancreatic ductal adenocarcinoma (PDAC) under chemotherapy
remain incompletely understood. The widespread use of neoadjuvant chemotherapy (NAC) …

The tumor microenvironment (TME) in pancreatic ductal adenocarcinoma (PDAC) is a
complex ecosystem that drives tumor progression; however, in-depth single cell …

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer entity characterized by a
heterogeneous genetic landscape and an immunosuppressive tumor microenvironment …